Re­gen­eron boost­ed, ri­val Es­pe­ri­on slammed as in­vestors scram­ble to catch up to a PC­SK9 price war

The big news over the week­end head­lined at #ACC18 in Or­lan­do, as Re­gen­eron $REGN and Sanofi $SNY pulled the cov­ers off of da­ta show­ing that their PC­SK9 drug Pralu­ent saved lives, while sig­nif­i­cant­ly cut­ting car­dio risks for pa­tients. And they im­me­di­ate­ly fol­lowed up with a ma­jor price dis­count for in­sur­ers which would drop the var­i­ous boo­bie traps meant to stop mem­bers from get­ting their hands on the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER